These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28623459)

  • 41. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
    Lee SC; Shimasaki N; Lim JSJ; Wong A; Yadav K; Yong WP; Tan LK; Koh LP; Poon MLM; Tan SH; Ow SGW; Bharwani L; Yap YS; Foo MZQ; Coustan-Smith E; Sundar R; Tan HL; Chong WQ; Kumarakulasinghe NB; Lieow JLM; Koe PJX; Goh BC; Campana D
    Clin Cancer Res; 2020 Sep; 26(17):4494-4502. PubMed ID: 32522887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.
    Misumi T; Tanabe K; Fujikuni N; Ohdan H
    PLoS One; 2018; 13(10):e0204880. PubMed ID: 30321186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
    Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity.
    Han D; Xu Y; Zhao X; Mao Y; Kang Q; Wen W; Yu X; Xu L; Liu F; Zhang M; Cui J; Wang Z; Yang Z; Du P; Qin W
    Biochem Biophys Res Commun; 2021 Jan; 534():134-140. PubMed ID: 33341068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High Numbers of Circulating CD57
    Muntasell A; Servitja S; Cabo M; Bermejo B; Pérez-Buira S; Rojo F; Costa-García M; Arpí O; Moraru M; Serrano L; Tusquets I; Martínez MT; Heredia G; Vera A; Martínez-García M; Soria L; Comerma L; Santana-Hernández S; Eroles P; Rovira A; Vilches C; Lluch A; Albanell J; López-Botet M
    Cancer Immunol Res; 2019 Aug; 7(8):1280-1292. PubMed ID: 31189644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural and functional characterization of a monoclonal antibody blocking TIGIT.
    Jeong BS; Nam H; Lee J; Park HY; Cho KJ; Sheen JH; Song E; Oh M; Lee S; Choi H; Yang JE; Kim M; Oh BH
    MAbs; 2022; 14(1):2013750. PubMed ID: 35090381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
    Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
    J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.
    Richards JO; Albers AJ; Smith TS; Tjoe JA
    Cancer Immunol Immunother; 2016 Nov; 65(11):1325-1335. PubMed ID: 27573917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.
    Stein N; Tsukerman P; Mandelboim O
    Hum Antibodies; 2017; 25(3-4):111-119. PubMed ID: 28035916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.
    Namba M; Hattori N; Hamada H; Yamaguchi K; Okamoto Y; Nakashima T; Masuda T; Sakamoto S; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Kohno N
    Cancer Lett; 2019 Feb; 442():31-39. PubMed ID: 30389434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
    Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
    Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells.
    Vendrame E; Seiler C; Ranganath T; Zhao NQ; Vergara R; Alary M; Labbé AC; Guédou F; Poudrier J; Holmes S; Roger M; Blish CA
    AIDS; 2020 May; 34(6):801-813. PubMed ID: 32028328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
    J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4
    Holder KA; Burt K; Grant MD
    Clin Transl Immunology; 2021; 10(10):e1348. PubMed ID: 34707863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.